Clin Mol Hepatol.
2020 Jul;26(3):312-314. 10.3350/cmh.2020.0099.
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
- Affiliations
-
- 1Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea
- KMID: 2504505
- DOI: http://doi.org/10.3350/cmh.2020.0099
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
- Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
- The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
- Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
- Management of Antiviral Resistance in Chronic Hepatitis B
